Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 657-663 , May 2011

Therapy of Sclerodermatous Chronic Graft-Versus-Host Disease with Mammalian Target of Rapamycin Inhibitors

  • Zuzana Jedlickova

      Affiliations

    • Centre for Bone Marrow and Blood Stem Cell Transplantation, Deutsche Klinik für Diagnostik, Wiesbaden, Germany
    • ,
  • Irina Burlakova

      Affiliations

    • Centre for Bone Marrow and Blood Stem Cell Transplantation, Deutsche Klinik für Diagnostik, Wiesbaden, Germany
    • ,
  • Gesine Bug

      Affiliations

    • Med. Klinik III, Goethe University, Frankfurt am Main, Germany
    • ,
  • Herrad Baurmann

      Affiliations

    • Centre for Bone Marrow and Blood Stem Cell Transplantation, Deutsche Klinik für Diagnostik, Wiesbaden, Germany
    • ,
  • Rainer Schwerdtfeger

      Affiliations

    • Centre for Bone Marrow and Blood Stem Cell Transplantation, Deutsche Klinik für Diagnostik, Wiesbaden, Germany
    • ,
  • Michael Schleuning

      Affiliations

    • Centre for Bone Marrow and Blood Stem Cell Transplantation, Deutsche Klinik für Diagnostik, Wiesbaden, Germany
    • Corresponding Author InformationCorrespondence and reprint requests: Prof. Dr. Michael Schleuning, Centre for Bone Marrow and Blood Stem Cell Transplantation, Deutsche Klinik für Diagnostik, Aukammallee 33, 65191 Wiesbaden, Germany.

Received 14 December 2009 ,Accepted 27 July 2010.

  • Image Result

    Kaplan-Meier estimates of overall survival since initiation of mTOR-I therapy comparing sirolimus and everolimus.

    Kaplan-Meier estimates of overall survival since initiation of mTOR-I therapy comparing sirolimus and everolimus.

 Financial disclosure: See Acknowledgment on page 662.

PII: S1083-8791(10)00326-5

doi: 10.1016/j.bbmt.2010.07.025

Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 657-663 , May 2011

Article Tools

* Image Usage & Resolution